Australia markets close in 34 minutes

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
158.00-0.25 (-0.16%)
At close: 04:03PM EDT
158.00 0.00 (0.00%)
After hours: 07:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close158.25
Bid0.00 x 1000
Ask0.00 x 800
Day's range156.36 - 159.70
52-week range134.09 - 175.91
Avg. volume6,411,436
Market cap278.734B
Beta (5Y monthly)0.59
PE ratio (TTM)23.83
Earnings dateN/A
Forward dividend & yield5.92 (3.74%)
Ex-dividend date13 Apr 2023
1y target estN/A
  • PR Newswire

    Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023

    Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from 30 March - 1 April 2023, supporting practitioners to help patients 'unlock their individuality' in an evolving world. Events include two Allergan Medical Institute (AMI) symposia, Meet the Expert sessions and an interactive exhibition booth that practitioners can explore. Throug

  • PR Newswire

    AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

    AbbVie (NYSE: ABBV) today announced topline results from a Phase 2 study of upadacitinib (RINVOQ®, 30 mg) given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once daily in patients with moderately to severely active systemic lupus erythematosus (SLE).1 The SLEek study met the primary endpoint of SLE Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in the upadacitinib 30

  • PR Newswire

    Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

    AbbVie (NYSE: ABBV) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab (SKYRIZI®,1200 mg intravenous [IV], at weeks 0, 4 and 8) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis.1 In the study, 20.3% of patients receiving risankizumab achieved clinical remission compared to 6.2% of patients receiving plac